Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP®) Biosimilar, to Those of NESP® After a Single Subcutaneous or Intravenous Administration to Healthy Subjects

Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP®) Biosimilar, to Those of NESP® After a Single Subcutaneous or Intravenous Administration to Healthy Subjects

Inseung Jeon,1,* Jaeseong Oh,1,* Yu-Kyung Kwon,2 Seo Hyun Yoon,1 Joo-Youn Cho,1 In-Jin Jang,1 Kyung-Sang Yu,1 SeungHwan Lee1 1Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea; 2Department of Clinical Research,...

Full description

Bibliographic Details
Main Authors:	Jeon I, Oh J, Kwon YK, Yoon SH, Cho JY, Jang IJ, Yu KS, Lee S
Format:	Article
Language:	English
Published:	Dove Medical Press 2021-04-01
Series:	Drug Design, Development and Therapy
Subjects:	pharmacokinetics pharmacodynamics biosimilar darbepoetin alfa
Online Access:	https://www.dovepress.com/comparison-of-pharmacokinetic-pharmacodynamic-and-tolerability-profile-peer-reviewed-fulltext-article-DDDT

Similar Items

Comparative efficacy and safety of biosimilar darbepoetin alfa in adults with anemia of chronic kidney disease
by: Prasad Apsangikar, et al.
Published: (2018-01-01)

Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon® and Eprex® following a single subcutaneous administration in healthy male volunteers
by: Yoon S, et al.
Published: (2017-10-01)

Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial
by: Shubhadeep D. Sinha, et al.
Published: (2019-03-01)

USE OF DARBEPOETIN ALFA (ARANESP®) FOR ANEMIA TREATMENT IN CHILDREN WITH CHRONIC KIDNEY DISEASE – CLINICAL EXPERIENCE OF BULGARIAN PEDIATRIC GROUP
by: Maria Gaydarova, et al.
Published: (2017-01-01)

A pharmacist‐managed dosing algorithm for darbepoetin alfa and iron sucrose in hemodialysis patients: A randomized, controlled trial
by: Francisca Johanna van denOever, et al.
Published: (2020-08-01)

Darbepoetin Alfa in Young Infants With Renal Failure: Single Center Experience, a Case Series and Review of the Literature
by: Anna Maria Libudzic-Nowak, et al.
Published: (2018-12-01)

Protective effects of Tadalafil and darbepoetin against ischemia - reperfusion injury in a rat testicular torsion model
by: Caglar Yildirim, et al.

The use of darbepoetin alpha in infants
by: A. V. Shchegolev, et al.
Published: (2019-06-01)

Randomized Study of Darbepoetin Alfa and Recombinant Human Erythropoietin for Treatment of Renal Anemia in Chronic Renal Failure Patients Receiving Peritoneal Dialysis
by: Wen-Yi Li, et al.
Published: (2008-11-01)

DETERMINATION OF DARBEPOETIN ALFA IN RABBIT PLASMA BY ELISA
by: M. V. Karlina, et al.
Published: (2019-01-01)

Bioequivalence of a biosimilar enoxaparin sodium to Clexane® after single 100 mg subcutaneous dose: results of a randomized, double-blind, crossover study in healthy volunteers
by: Martínez González J, et al.
Published: (2018-03-01)

A cost-effectiveness evaluation comparing originator follitropin alfa to the biosimilar for the treatment of infertility
by: Gizzo S, et al.
Published: (2016-12-01)

SEARCH OF NEW PHARMACEUTICALS ON THE BASIS OF DARBEPOETIN IN THE TREATMENT OF ISCHEMIC STROKE (REVIEW OF LITERATURE)
by: Konstantin Reznikov, et al.
Published: (2017-03-01)

The efficacy of darbepoetin alpha in hemodialysis patients resistant to human recombinant erythropoietin (rHuEpo)
by: Hejaili Fayez
Published: (2009-01-01)

Darbepoetin Use for the Treatment of Anemia in Hemodialysis Patients in Saudi Arabia
by: Shaheen Faissal, et al.
Published: (2006-01-01)

Major results of a phase III comparative multicenter study on the follitropin alfa biosimilar (Primapur®) and the original follitropin alfa (Gonal-f®)
by: Z. B. Barakhoeva, et al.
Published: (2018-11-01)

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
by: Choi C, et al.
Published: (2018-08-01)

Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis
by: Su Jen Chua, et al.
Published: (2021-04-01)

Infantile Pyknocytosis: End-Tidal CO, %Micro-R Measurements, Next-Generation Sequencing, and Transfusion Avoidance with Darbepoetin
by: Timothy M. Bahr, et al.
Published: (2020-12-01)

Comparison of the pharmacokinetic and pharmacodynamic properties of two recombinant granulocyte colony-stimulating factor formulations after single subcutaneous administration to healthy volunteers
by: Audrius Sveikata, et al.
Published: (2014-01-01)

A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects
by: Hong Zhang, et al.
Published: (2020-10-01)

NESP: 22 anos dedicados à saúde brasileira
by: Edgar Merchan Hamann
Published: (2009-01-01)

Quantification of polysorbate 80 in biopharmaceutical formulations implementing an optimized colorimetric approach
by: A. S. Seregin, et al.
Published: (2020-07-01)

Hemoglobin levels and quality of life in patients with symptomatic chemotherapy-induced anemia: the eAQUA study
by: Mouysset JL, et al.
Published: (2016-01-01)

Comparative Studies of Biosimilar Medicinal Products
by: O. B. Talibov
Published: (2019-06-01)

Editorial, v.13, n.esp1, maio (2017)
by: José Luís Bizelli, et al.
Published: (2018-04-01)

Biosimilar Retacrit® (epoetin zeta) in the treatment of chemotherapy-induced symptomatic anemia in hematology and oncology in Germany (ORHEO) – non-interventional study
by: Losem C, et al.
Published: (2017-02-01)

Results of the Estimation of Biosimilarity of RinLiz<sup>®</sup> (LLC «GEROPHARM», Russia) and Humalog<sup>®</sup> (Lilly France, France) Using the Method of the Hyperinsulinemic Eulygemic Clamp on Healthy Voluntary
by: A. Yu. Mayorov, et al.
Published: (2020-05-01)

Biosimilars in rheumatology and other fields of medicine
by: Marcin Milchert, et al.
Published: (2014-07-01)

A randomized crossover study of single biweekly administration of epoetin-α compared with darbepoetin-α in chronic kidney disease patients not receiving dialysis
by: Ha-Young Na, et al.
Published: (2014-12-01)

Glycosylation Pattern and in vitro Bioactivity of Reference Follitropin alfa and Biosimilars
by: Laura Riccetti, et al.
Published: (2019-07-01)

Authorisation of Non-Innovator Biotherapeutic (Biosimilar) Products in the USA
by: A. A. Soldatov, et al.
Published: (2019-03-01)

Biosimilars and Switching: What Is Your Perspective?
by: Sandoz
Published: (2017-08-01)

On the Regulatory Approval Pathway of Biosimilar Products
by: Jun Wang, et al.
Published: (2012-03-01)

Antibody-mediated pure red cell aplasia after treatment with darbepoetin-alpha postrenal transplantation
by: Badarinath Vellaboina, et al.
Published: (2019-01-01)

Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg®, a pegfilgrastim biosimilar in healthy subjects
by: Karsten Roth, et al.
Published: (2019-10-01)

Pharmacodynamics, safety, and immunogenicity of Pelmeg®, a pegfilgrastim biosimilar in healthy subjects
by: Hendrik Wessels, et al.
Published: (2019-10-01)

Pharmacoeconomic analysis of using the darbepoetin alfa to correct anemia in patients with chronic renal failure who are on hemodialysis or peritoneal dialysis
by: I. S. Krysanov, et al.
Published: (2018-05-01)

THE NOVEL BIOSIMILAR OF FOLLITROPIN ALPHA TO BE MANUFACTURED IN RUSSIA STARTING FROM 2017
by: I. I. Vorobiev, et al.
Published: (2017-12-01)

Biosimilars: presumption of guilt
by: Marina Vladimirovna Shestakova, et al.
Published: (2011-12-01)